一张罚单揭开麻醉药涨价超10倍之谜，上海医药旗下公司频被罚

Core Viewpoint - The case involving the price manipulation of the anesthetic drug, Xinsiming Injection, reveals a significant increase in its price due to collusion among major sales companies, leading to penalties exceeding 200 million yuan for the involved parties [1][2][10]. Group 1: Price Manipulation and Market Impact - Xinsiming Injection's price surged by 11-21 times due to a collusion agreement among Shanghai Xinyi United Pharmaceutical Co., Ltd., Henan Runhong Pharmaceutical Co., Ltd., and Chengdu Huixin Pharmaceutical Co., Ltd. [1][10] - The drug, which is essential for surgeries and other medical treatments, was previously priced between 3.56-6.8 yuan per unit before the collusion, and later reached prices of 71.5 yuan, 36 yuan, and 35.8 yuan in different markets [6][7]. - The total procurement amount for Xinsiming Injection in hospitals was reported at 776 million yuan in 2021, with sales revenue for the drug reaching 511 million yuan for the same year [8]. Group 2: Regulatory Actions and Penalties - The Shanghai Municipal Market Supervision Administration imposed a total fine of 222 million yuan on the three companies involved, with Xinyi United facing the heaviest penalty of 165 million yuan [9][11]. - The case marked the first instance of individual accountability under the revised Anti-Monopoly Law, with personal fines imposed on individuals responsible for the collusion [12]. - Following the investigation, Xinsiming Injection was included in the national centralized procurement list, resulting in a significant price drop to between 0.56 yuan and 0.91 yuan per unit [14]. Group 3: Company Background and Previous Violations - Shanghai Xinyi United and its parent company, Shanghai Pharmaceuticals Holding Co., Ltd., have a history of regulatory violations, including previous penalties for accounting irregularities and price manipulation [15][17]. - The recent penalties are not expected to have a significant impact on Shanghai Pharmaceuticals' overall operations, as the affected business unit contributes less than 1% to the company's total revenue [15].